echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Protect women's health and create miracles of life - "Create a new chapter, gain youth" 2022 Women's Oncology Summit ended successfully

    Protect women's health and create miracles of life - "Create a new chapter, gain youth" 2022 Women's Oncology Summit ended successfully

    • Last Update: 2022-01-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    *Only for medical professionals to read and reference Focus on women's health and build a harmonious society
    .

    In order to further promote the development of female cancer research and improve the overall level of female cancer diagnosis and treatment, on January 16, 2022, the 2022 Women's Oncology Summit, hosted by the Beijing Kanghua Chinese and Western Medicine Development Foundation, officially kicked off.

    .

    This summit adopts a combination of online and offline.
    There are 31 sub-venues in 16 cities offline.
    Top experts in the field of female oncology are invited to discuss the quality control of gynecological oncology diagnosis and treatment, and female oncology through academician forums and summit forums.
    Conduct multi-level, multi-angle and multi-disciplinary discussions on big data research, the current status and trends of global anti-tumor drug research and development, and the current and future of breast cancer translational research, providing clinicians and basic researchers with an exchange of experience and updates.
    platform of ideas
    .

    The meeting started with opening speeches by academicians Martin and Xu Binghe of the Chinese Academy of Engineering
    .

    The two academicians said that the meeting was of great significance and hoped to update the consensus through this meeting, so as to benefit more female cancer patients
    .

    Hosted by Professor Jiang Zefei and Professor Ren Guosheng, the three academicians opened the academician forum
    .

    In the academician forum, Prof.
    Jiang Zefei first chaired it.
    Academician Martin of Chinese Academy of Engineering and Academician Xu Binghe of Chinese Academy of Engineering had an academician dialogue on "how to carry out interdisciplinary cooperation in the field of gynecological tumor and breast tumor"
    .

    Afterwards, Academician Martin of the Chinese Academy of Engineering elaborated on the "NUWA China Gynecological Oncology Big Data Platform Construction and Application".
    The study mentioned that "through a large-scale real-world study, the real data of Chinese ovarian cancer patients was obtained, and the results were generated through the analysis of the results.
    High-quality evidence-based medical evidence provides a basis for relevant diagnosis and treatment norms, and then improves and optimizes clinical practice to benefit the vast number of patients
    .

    " In response to the topic "Global Anti-tumor Drug Research and Development Status and Trends", Academician Xu Binghe of the Chinese Academy of Engineering carried out With in-depth research, there is currently a dazzling array of drug researches around the world around targeted therapy, dual antibody therapy, ADC therapy, cell therapy, and immunotherapy.
    Breakthrough drug research and development provide new hope for the treatment of cancer patients around the world
    .

    China's anti-tumor drug research has also made great progress, and the number of drugs under development has increased significantly
    .

    Academician Song Erwei from the Chinese Academy of Sciences discussed the present and future of breast cancer translational research, introducing the translational research progress of immunotherapy, triple-negative breast cancer, and HR-positive breast cancer precision treatment, as well as artificial intelligence in breast cancer screening.
    and exploration of prognostic risk judgment
    .

    In 2021, female cancer treatment will enter a new stage of development
    .

    In the annual inventory, Professor Shen Zhenzhou presided over the annual review and outlook in the field of breast tumors.
    Professor Shao Zhimin pointed out that the release of the 2021 blockbuster research data will further change the prognosis of patients, whether it is the OlypmiA study of olaparib adjuvant therapy for one year to reduce gBRCA mutation The recurrence risk of HER2-negative early breast cancer is 42%, and the MonrchE abecici endocrine enhancement reduces the recurrence risk of patients by 30%, both of which promote early breast cancer to be further cured
    .

    In the treatment of advanced breast cancer, the Destiny Breast-03 study established the second-line standard for HER2-positive metastatic breast cancer and greatly improved the long-term survival of patients
    .

    In terms of triple-negative breast cancer, whether it is KN522, KN355 or FUTURE C-plus led by Prof.
    Shao Zhimin's team, they will further explore the benefits of immunotherapy for triple-negative breast cancer patients
    .

    Professor Xie Xing presided over the annual review and outlook in the field of gynecological oncology.
    Professor Wu Xiaohua, Professor Kong Beihua, and Professor Wu Lingying discussed the new progress in surgical treatment of gynecological tumors, the new progress in chemotherapy and maintenance therapy, and the new progress in targeted maintenance therapy
    .

    The three professors pointed out that the new progress in surgery, chemotherapy and targeted maintenance therapy has brought a new dawn to further improve the survival rate and quality of life of gynecological cancer patients
    .

    It is very gratifying to see that the update of the data of PARP inhibitor (PARPi) in the Chinese population adds to the evidence for the benefit of PARPi in the Chinese population
    .

    The L-MOCA study showed that, regardless of the presence or absence of BRCA gene mutation, olapa was significantly beneficial to the maintenance treatment of patients with platinum-sensitive recurrent ovarian cancer, and the median PFS of the second-line PSR population was up to 18 months
    .

    The OReO study provides data support for whether PARPi can be used again after PARPi
    .

    In ovarian cancer patients who had previously received multiple lines of therapy, including PARPi maintenance, repeat olaparib maintenance therapy significantly improved PFS, regardless of BRCAm status
    .

    Ms.
    Li Xiaoshi, Secretary General of Beijing Kanghua Chinese and Western Medicine Development Foundation, delivered a speech on behalf of the organizers of the conference
    .

    Ms.
    Xie Qiong, Ms.
    Tian Yu and Ms.
    Wang Yingyi delivered speeches on behalf of AstraZeneca China Oncology Division, Merck China Oncology Division and Daiichi Sankyo Oncology Division
    .

    The three company representatives thanked the academicians and experts for their presence, and said that they would work with the experts to continue to promote closer cooperation with female oncology experts, focusing on patients, to bring more hope to Chinese female oncology patients.

    .

    Left: Ms.
    Xie Qiong, Vice President of AstraZeneca China Oncology Business Unit Middle: Ms.
    Tian Yu, Vice President of Merck China Oncology Business Unit Right: Ms.
    Wang Yingyi, General Manager of Daiichi Sankyo (China) Oncology Business Headquarters Then, Sixteen Cities (Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Wuhan, Urumqi, Shanghai, Shenyang, Xi'an, Zhengzhou) opened the exciting sessions of the sub-venues, with 46,338 people attending the conference online and offline
    .

    The summit was full of splendid contents.
    It brought together top domestic experts in the field of female tumors.
    They not only shared the current situation and development of female tumors, but also discussed and commented on the issues of Chinese female tumors in different dimensions, expanding clinical horizons and developing scientific research thinking.
    It is of great significance to promote the standardized diagnosis and treatment of female tumors, light up the life of tumor patients, and create miracles of life
    .

    *This article is only used to provide scientific information to medical professionals and does not represent the views of this platform
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.